135 completed, 13 terminated, 6 active not recruiting, 6 unknown. 169 Phase 3, 15 Phase 2.
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID, CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID - Cystic Fibrosis (CF), Chronic Rhinosinusitis (CRS) | Phase 3 | Recruiting | Indiana University | 64 | 2025-07-02 | 2025-12-16 |
| Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis Rifaximin 550 MG Oral Tablet [XIFAXAN], Placebo - Cystic Fibrosis, Abdominal Pain | Phase 2 / Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2025-07-01 | 2025-06-27 | |
| Assessing Tenapanor as a Treatment of CF-related Constipation. Tenapanor - Cystic Fibrosis, Constipation | Phase 3 | Active not recruiting | Massachusetts General Hospital | 25 | 2025-06-01 | 2026-08-21 |
| Maralixibat in Patients With Cystic Fibrosis and Constipation Maralixibat 9.5 MG/ML [Livmarli] - Constipation Chronic Idiopathic, Cystic Fibrosis | Phase 2 / Phase 3 | Recruiting | Children's Hospital Los Angeles | 20 | 2025-04-09 | 2026-04-21 |
| Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 50 | 2024-11-21 | 2026-06-05 |
| SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes Empagliflozin, Placebo Control - Cystic Fibrosis-related Diabetes, Cystic Fibrosis | Phase 2 / Phase 3 | Active not recruiting | University of Minnesota | 8 | 2024-01-08 | 2026-09-21 |
| Semaglutide in CFRD Semaglutide - Cystic Fibrosis, Cystic Fibrosis-related Diabetes | Phase 2 / Phase 3 | Completed | University of Minnesota | 8 | 2023-10-16 | 2026-01-21 |
| Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older VNZ/TEZ/D-IVA - Cystic Fibrosis | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 174 | 2023-08-11 | 2026-04-29 |
| Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 67 | 2023-06-27 | 2026-10-15 |
| Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 297 | 2022-11-23 | 2026-10-27 |
| A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy VX-121/TEZ/D-IVA - Cystic Fibrosis | Phase 3 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 822 | 2022-11-08 | 2026-10-09 |
| Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age VX-121/TEZ/D-IVA - Cystic Fibrosis | Phase 3 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 210 | 2022-06-21 | 2026-05-28 |
| Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation ELX/TEZ/IVA, IVA, Placebo (matched to ELX/TEZ/IVA) - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 307 | 2022-05-09 | 2024-08-01 |
| Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 71 | 2022-01-17 | 2026-03-03 |
| A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF) ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 86 | 2022-01-14 | 2023-07-11 |
| A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 597 | 2021-10-27 | 2024-06-13 |
| A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF) ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 82 | 2021-10-12 | 2025-09-24 |
| A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF) VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | Vertex Pharmaceuticals Incorporated | 435 | 2021-09-14 | 2024-10-03 |
| A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis OligoG Dry powder for inhalation - Cystic Fibrosis | Phase 2 / Phase 3 | Withdrawn | AlgiPharma AS | 2021-09-01 | 2022-06-30 | |
| A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection Posaconazole 100 MG [Noxafil], Posaconazole 40 MG/ML - Cystic Fibrosis, Aspergillosis | Phase 2 / Phase 3 | Unknown | Bambino Gesù Hospital and Research Institute | 135 | 2021-04-22 | 2021-07-19 |
Showing 20 of 169. Sign in to see all of them.
Exocrine Pancreatic Insufficiency (17) · Lung Diseases (10) · Pseudomonas Infections (10) · Respiratory Tract Diseases (6) · Diabetes Mellitus (5) · Genetic Diseases, Inborn (5) · Inflammation (4) · Pancreatic Diseases (4) · Pathologic Processes (4) · Respiratory Tract Infections (4) · Steatorrhea (4) · Digestive System Diseases (3) · Fibrosis (3) · Abdominal Pain (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (169) · Infant, Newborn, Diseases (167) · Digestive System Diseases (166) · Pancreatic Diseases (165) · Genetic Diseases, Inborn (164) · Respiratory Tract Diseases (163) · Lung Diseases (159) · Infections (20) · Pathological Conditions, Signs and Symptoms (16) · Bacterial Infections and Mycoses (13) · Nutritional and Metabolic Diseases (12) · Bacterial Infections (11) · Gram-Negative Bacterial Infections (11) · Metabolic Diseases (11) · Pathologic Processes (7)
ivacaftor (56) · elexacaftor, ivacaftor, tezacaftor drug combination (21) · tezacaftor, ivacaftor drug combination (9) · Inhalation (8) · lumacaftor (7) · Tobramycin (6) · Sodium Chloride (5) · ataluren (5) · liprotamase lipase (5) · Aztreonam (4) · dornase alfa (4) · lumacaftor, ivacaftor drug combination (4) · tezacaftor (4) · Cholecalciferol (3) · Pancrelipase (3)
Vertex Pharmaceuticals Incorporated (62) · Gilead Sciences (9) · Forest Laboratories (6) · Anthera Pharmaceuticals (5) · Novartis Pharmaceuticals (5) · PTC Therapeutics (5) · University of Minnesota (4) · Insmed Incorporated (3) · Merck Sharp & Dohme LLC (3) · Solvay Pharmaceuticals (3) · Syntara (3) · The Hospital for Sick Children (3) · Amgen (2) · Assistance Publique - Hôpitaux de Paris (2) · Chiesi Farmaceutici S.p.A. (2)
United States (106) · Canada (76) · Germany (62) · United Kingdom (62) · Australia (59) · France (56) · Belgium (41) · Spain (40) · Italy (39) · Netherlands (33) · Ireland (31) · Israel (27) · Denmark (24) · Switzerland (23) · Poland (22)
Antoinette Moran, MD (3) · Gina Eagle, MD (3) · Joseph McIntosh, MD (3) · Mark Bresnik, MD (3) · Bruce Montgomery, MD (2) · Felix Ratjen, MD (2) · Henryk Mazurek, Doctor (2) · Monica Gangal (2) · Temitayo Ajayi, MD (2) · Adebayo Lawal, M.D. (1) · Adilia Warris, Prof (1)
PMID 37983082, PMID 33331662, PMID 36509366, PMID 32761612, PMID 36866921, PMID 24464974, PMID 25981758, PMID 26070913, PMID 26709158, PMID 27298017, PMID 30146268, PMID 30587335, PMID 32358807, PMID 37319354, PMID 39756424, PMID 15756212, PMID 16421364, PMID 18658109, PMID 19420195, PMID 19447923, PMID 19592632, PMID 19643946, PMID 19683970, PMID 19805710, PMID 19815466, PMID 19996339, PMID 20171415, PMID 20435858, PMID 21169471, PMID 21441078, PMID 21478216, PMID 21681115, PMID 22198974, PMID 22682898, PMID 22985692, PMID 23588193, PMID 23590265, PMID 23672633, PMID 23809507, PMID 24429202, PMID 24571729, PMID 24586292, PMID 24594542, PMID 24620855, PMID 24836205, PMID 25029347, PMID 25066363, PMID 25311995, PMID 25458463, PMID 25819269
2017 (9), 2018 (8), 2019 (7), 2014 (4), 2008 (3), 2009 (3), 2015 (3), 2016 (3), 2023 (2), M01RR002558 (1), U01HL114589 (1), U01HL114623 (1)